2′-C-Methyl branched pyrimidine ribonucleoside analogues: Potent inhibitors of RNA virus replication

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 4, 2007, Pages 225-242

  Benzaria, Samira ^a,b   Bardiot, Dorothée ^a   Bouisset, Tony ^a,b   Counor, Clément ^a,b   Rabeson, Céline ^a,b   Pierra, Claire ^a,b   Storer, Richard ^b,c   Loi, Anna Giulia ^d   Cadeddu, Alessandra ^d   Mura, Massimo ^d   Musiu, Chiara ^d   Liuzzi, Michel ^d   Loddo, Roberta ^d   Bergelson, Svetlana ^e,f   Bichko, Vadim ^f   Bridges, Edward ^f   Cretton Scott, Erika ^f   Mao, John ^f,g   Sommadossi, Jean Pierre ^f   Seifer, Maria ^f   Standring, David ^f   Tausek, Michele ^f   Gosselin, Gilles ^a,b   La Colla, Paolo ^d   more..

^a CNRS   (France)

^b Laboratoires IDENIX Sarl   (France)

^c VASTox plc   (United Kingdom)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e BIOGEN   (United States)

^f Idenix Pharmaceuticals Inc   (United States)

^g Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

2 C methylnucleosides; D and L enantiomers; HCV; RNA viruses; SATE pronucleotides

Indexed keywords

2' C METHYL BETA CYTIDINE; 2' C METHYL BETA RIBOTHYMIDINE; 2' C METHYL BETA URIDINE; 2' C METHYL CYTIDINE; 2' C METHYL THYMIDINE; 2' C METHYL URIDINE; ANTIVIRUS AGENT; DOUBLE STRANDED RNA; O (2' C METHYL BETA CYTIDIN 5' YL)O',O'' BIS(PIVALOYL 2 THIOETHYL)PHOSPHATE; O (2' C METHYL BETA DEXTRO URIDIN 5' YL)O',O'' BIS(PIVALOYL 2 THIOETHYL)PHOSPHATE; O (2' C METHYL BETA URIDIN 5' YL)O',O'' BIS(PIVALOYL 2 THIOETHYL)PHOSPHATE; PYRIMIDINE RIBONUCLEOSIDE DERIVATIVE; RNA DIRECTED RNA POLYMERASE; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; PYRIMIDINE NUCLEOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOVINE DIARRHEA VIRUS; CELL METABOLISM; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; RNA REPLICATION; RNA VIRUS; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DRUG EFFECT; HAMSTER; HAPLORHINI; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DOGS; HAPLORHINI; HUMANS; MOLECULAR STRUCTURE; PYRIMIDINE NUCLEOSIDES; RNA VIRUSES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 34848918867     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800406     Document Type: Article

References (73)

1. Adfhal N, Rodriguez-Torres M, Lawitz E, Godofsky E, Chao G, Fielman B & Brown N (2005) Enhanced antiviral efficacy for valopicitabine (NM283) plus PEG-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial. Journal of Hepatology 42 Suppl 2:39-40.
2. 6-modified nucleosides. (Ribapharm, Inc.) WO 2004065398.
3. Beigelman LN, Ermolinski BS, Gurskaya GV, Tsapkina EN, Karpeisky MY & Mikhailov SN (1987) New syntheses of 2′-C-methylnucleosides starting from D-glucose and D-ribose. Carbohydrate Research 166:219-232.
4. Benzaria S, Pélicano H, Johnson R, Maury G, Imbach JL, Aubertin AM, Obert G & Gosselin G (1996) Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl] adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. Journal of Medicinal Chemistry 39:4958-4965.
5. Blackburn GM & Gait MJ (Editors) 1996. Nucleic acids in chemistry and biology. Oxford: Oxford University Press.
6. Buckwold VE, Beer BE & Donis RO (2003) Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Research 60:1-15.
7. Burgess K & Cook D (2000) Syntheses of nucleoside triphosphates. Chemical Reviews 100: 047-2059.
8. Cahard D, McGuigan C & Balzarini J (2004) Aryloxy phosphoramidate triesters as pro-tides. Mini-Reviews in Medicinal Chemistry 4:371-381.
9. Carroll SS, LaFemina RL, Hall DL, Himmelberger AL, Kuo LC, MacCoss M, Olsen DB, Rutkowski CA, Tomassini JE, An H, Bhat B, Bhat N, Dan Cook P, Eldrup AB, Guinosso CJ, Prhavc M & Prakash TP (2002) Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. (Merck & Co., Inc., Isis Pharmaceuticals, Inc.) WO 2002057425.
10. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M & Olsen DB (2003) Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. Journal of Biological Chemistry 278:11979-11984.
11. Cui L, Schinazi RF, Gosselin G, Imbach J-L, Chu CK, Rando RF, Revankar GR & Sommadossi J-P (1996) Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Biochemical Pharmacology 52:1577-1584.
12. De Clercq E (2004) Antivirals and antiviral strategies. Nature Reviews Microbiology 2:704-720.
13. De Francesco R, Tomei L, Altamura S, Summa V & Migliaccio G (2003) Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Research 58:1-16.
14. Ding Y, Girardet J-L, Hong Z, Lai VCH, An H, Koh Y-H, Shaw SZ & Zhong W (2005) Synthesis of 9-(-2-β-C-methyl-β-D- ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication. Bioorganic & Medicinal Chemistry Letters 15:709-713.
15. Driscoll JS (2002) Antiviral drugs. Hampshire, England; Burlington, VT: Ashgate Publishing.
16. Drontle DP & Wagner CR (2004) Designing a pronucleotide stratagem: lessons from amino acid phosphoramidates of anticancer and antiviral pyrimidines. Mini-Reviews in Medicinal Chemistry 4:409-419.
17. Du J, Choi Y, Lee K, Chun BK, Hong JH & Chu CK (1999) A practical synthesis of L-FMAU from L-arabinose. Nucleosides & Nucleotides 18:187-195.
18. Eldrup AB, Allerson CR, Bennet CF, Beta S, Bhat B, Bhat N, Bosserman MR, Brooks J, Burlein C, Carroll SS, Dan Cook P, Getty KL, MacCoss M, McMasters DR, Olsen DB, Prakash TP, Prhavc M, Song Q, Tomassini JE & Xia J (2004a) Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. Journal of Medicinal Chemistry 47:2283-2295.
19. Eldrup AB, Prhavc M, Brooks J, Bhat B, Prakash TP, Song Q, Bera S, Bhat N, Dande P, Dan Cook P, Bennet CF, Carroll SS, Ball RG, Bosserman M, Burlein C, Colwell LF, Fay JF, Flores OA, Getty K, LaFemina R, Leone J, MacCoss M, McMasters DR, Tomassini JE, Von Lagen D, Wolanski B & Olsen DB (2004b) Structure-activity relationship of heterobase-modified 2′-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. Journal of Medicinal Chemistry 47:5284-5297.
20. 2Y-purinoreceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5′-triphosphate. Journal of Medicinal Chemistry 36:3937-3946.
21. Focher F, Spadari S & Maga G (2003) Antivirals at the mirror: the lack of stereospecificity of some viral and human enzymes offers novel opportunities in antiviral drug development. Current Drug Targets: Infectious Disorders 3:41-53.
22. Gumina G, Chong Y, Choo Y, Song GY & Chu CK (2002) L-Nucleosides: antiviral activity and molecular mechanism. Current Topics in Medicinal Chemistry 2:1065-1086.
23. Gutenkust DE & Malmquist WA (1963) Separation of soluble antigen and infectious particles of bovine viral diarrhea viruses and their relationship to hog cholera. Canadian Journal of Comparative Medicine & Veterinary Science 27:121-123.
24. Harry-O'kuru RE, Kryjak EA & Wolfe MS (1997a) 2′-C- alkylribonucleosides: design, synthesis, and conformation. Nucleosides & Nucleotides 16:1457-1460.
25. Harry-O'kuru RE, Smith JM & Wolfe MS (1997b) A short, flexible route toward 2′-C-branched ribonucleosides. Journal of Organic Chemistry 62:1754-1759.
26. Hong Z, An H, Ding Y, Girardet J-L & Zhong W (2003) Preparation of sugar modified nucleosides as antiviral agents. (Ribapharm, Inc.) WO 2003062255.
27. Hugle T & Cerny A (2003) Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Reviews in Medical Virology 13:361-371.
28. Kim MJ, Zhong W, Hong Z & Kao CC (2000) Template nucleotide moieties required for de novo initiation of RNA synthesis by a recombinant viral RNA-dependent RNA polymerase. Journal of Virology 74:10312-10322.
29. Klumpp K, Lévêque V, Le Pogam,S, Ma H, Jiang W-R, Kang H, Granycome C, Singer M, Laxton C, Qi Hang J Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Najera I (2006) The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture Journal of Biological Chemistry 281:3797-3799.
30. Koonin EV & Dolja W (1993) Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences. Critical Reviews in Biochemistry and Molecular Biology 28:375-430.
31. Krajewska E & Shugar D (1975) Alkylated cytosine nucleosides: substrate and inhibitor properties in enzymatic deamination. Acta Biochimica Polonica 22:185-194.
32. Kries W, Watanabe KA & Fox JJ (1978) Structural requirements for the enzymatic deamination of cytosine nucleosides. Helvetica Chimica Acta 61:1011-1016.
33. Krise JP & Stella VJ (1996) Prodrugs of phosphates, phosphonates, and phosphinates. Advanced Drug Delivery Reviews 19:287-310.
34. Lefebvre I, Périgaud C, Pompon A, Aubertin A-M, Girardet J-L, Kirn A, Gosselin G & Imbach J-L (1995) Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′- dideoxythymidine 5′-monophosphate. Journal of Medicinal Chemistry 38:3941-3950.
35. Legorburu U, Reese CB & Song Q (1999) Conversion of uridine into 2′-O-(2-methoxyethyl)uridine and 2′-O-(methoxyethyl) cytidine. Tetrahedron 55:5635-5640.
36. Ludwig J (1981) A new route to nucleoside 5′-triphosphate. Acta Biochimica Biophysica Academiae Scientiarum Hungaricae 16:131-133.
37. Madin SH & Darby Jr. NB (1958) Established kidney cell lines of normal adult bovine and ovine origin. Proceedings of the Society for Experimental Biology and Medicine 98:574-576.
38. Mathé C & Gosselin G (2006) L-Nucleoside enantiomers as antirals drugs: A mini-review. Antiviral Research 71:276-281.
39. Matsuda A, Itoh H, Takenuki K, Sasaki T & Ueda T (1988) Alkyl addition reaction of pyrimidine 2′-ketonucleosides: synthesis of 2′-branched-chain sugar nucleosides (Nucleosides and nucleotides. LXXXI). Chemical & Pharmaceutical Bulletin 36:945-953.
40. McHutchison JG, Bartenschlager R, Patel K & Pawlotsky J-M (2006) The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice. Journal of Hepatology 44:411-421.
41. Meier C, Ruppel MF, Vukadinovic D & Balzarini J (2004) 'Lock-in'-cycloSal-pronucleotides. A new generation of chemical Trojan horses? Mini-Reviews in Medicinal Chemistry 4:383-394.
42. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, L., Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, DJ Hazuda & OA Flores (2003) Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. Journal of Biological Chemistry 278:49164-49170.
43. Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochich Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA (2007) Mechanism and activation of β-D-2′-deoxy-2′-fluoro-2′-C- methylcytidine and inhibition of hepatitis C virus NSB RNA polymerase Antimicrobial Agents and Chemotherapy 51:503-509.
44. Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina R, Markel EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M, Hazuda DJ & Carroll SS (2004) A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrobial Agents & Chemotherapy 48: 3944-3953.
45. Parashar, UD, Bresee JS & Glass RI (2003) The global burden of diarrhoeal disease in children. Bulletin of the World Health Organization 81:236.
46. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Deamyster J & De Clercq E (1998) A rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20:309-321.
47. Périgaud C, Gosselin G, Lefebvre I, Girardet J-L, Benzaria S, Barber I & Imbach J-L (1993) 'SATE' and 'DTE' as enzyme-labile transient phosphate protecting groups. Bioorganic & Medicinal Chemistry Leters. 3:2521-2526.
48. Peyrottes S, Egron D, Lefebvre I, Gosselin G, Imbach J-L & Périgaud C (2004) SATE pronucleotide approach: an overview. Mini-Reviews in Medicinal Chemistry 4:395-408.
49. Pierra C, Amador A, Benzaria S, Cretton-Scott E, D'Amours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN, Sommadossi J-P, Storer R & Gosselin G (2006) Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Journal of Medicinal Chemistry 49:6614-6620.
50. Placidi L, Faraj A, Pierra C, Egron D, Cretton-Scott E, Gosselin G, Périgaud C, Martin LT, Schinazi RF, Imbach J-L, El Kouni MH, Bryant ML & Sommadossi J-P (2001) Antiviral activity and intracellular metabolism of bis(tbutylSATE) phosphotriester of β-L-2′,3′- dideoxyadenosine, a potent inhibitor of HIV and HBV replication. Antiviral Chemistry & Chemotherapy 12:99-108.
51. Prakash TP, Prhavc M, Eldrup AB, Dan Cook P, Carroll SS, Olsen DB, Stahlhut MW, Tomassini JE, MacCoss M, Galloway SM, Hilliard C & Bhat B (2005) Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5′-monophosphates as inhibitors of hepatitis C virus RNA replication. Journal of Medicinal Chemistry 48:1199-1210.
52. Recondo EF & Rinderknet H (1959) 121. Eine neue, einfache Synthese des 1-O-Acetyl-2,3,5-tri-O-benzoyl-β-D- ribofuranosides [A new and easy synthesis of 1-O-Acetyl-2,3,5-tri- O-benzoyl-β-D-ribofuranosides]. Helvetica Chimica Acta 12:1171-1173.
53. Roberts CD, Dyatkina NB, Keicher JD, Liehr SJR & Hanson EJ (2003) Preparation of nucleoside derivatives for treating hepatitis C virus infection. (Genelabs Technologies, Inc.) WO 2003093290.
54. Schultz C (2003. Prodrugs of biologically active phosphate esters. Bioorganic and Medicinal Chemistry 11:885-898.
55. Sommadossi J-P & La Colla P (2001a) Methods and compositions using modified nucleosides for treating flaviviruses and pestiviruses. (Novirio Pharmaceuticals Limited, Universita Degli Studi Di Cagliari) WO 2001092282.
56. Sommadossi J-P & La Colla P (2001b) Preparation of antiviral nucleosides and methods for treating hepatitis C virus. (Novirio Pharmaceuticals Limited, Universita Degli Studi Di Cagliari) WO 2001090121.
57. Standring DN, Lanford R, Wright T, Chung RT, Bichko V, Cretton-Scott E, Pan-Zhou X, Bergelson S, Qu L, Tausek M, Bridges EG, Moussa A, Storer R, Pierra C, Benzaria S, G Gosselin, La Colla P & Sommadossi J-P (2003) NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. Journal of Hepatology 38 Suppl 2:3.
58. Tang X-Q, Liao X & Piccirilli JA (1999) 2′-C-branched ribonucleosides: synthesis of the phosphoramidite derivatives of 2′-C-β-methylcytidine and their incorporation into oligonucleotides. Journal of Organic Chemistry 64:747-754.
59. Tomassini JE, Getty K, Stahlhut MW, Shim S, Bhat B, Eldrup AB, Prakash TP, Carroll SS, Flores O, MacCoss M, McMasters DR, Migliaccio G & Olsen DB (2005) Inhibitory effect of 2′-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrobial Agents and Chemotherapy 49:2050-2058.
60. Van Vliet KE, Glimaker M, Lebon P, Klapper PE, Taylor CE Ciardi M, Van Der Avoort HGAM, Dirpersloot RJA, Kurtz J, Peeters MF, Cleator GM & Van Loon AM (1998) Multicenter evaluation of the Amplicor Enterovirus PCR test with cerebrospinal fluid from patients with aseptic meningitis.' Journal of Clinical Microbiology 36:2652-2657.
61. Vorbruggen H & Bennua B (1981) A new simplified nucleoside synthesis. Chemische Berichte 114:1279-1286.
62. Vorbruggen H, Krolikiewicz K & Bennua B (1981) Nucleoside synthesis with trimethylsilyl triflate and Perchlorate as catalysts. Chemische Berichte 114:1234-1255.
63. Walker MP, Appleby TC, Zhong W, Lau JYN & Hong Z (2003). Hepatitis C virus therapies: current treatments, targets and future perspectives. Antiviral Chemistry & Chemotherapy 14:1-21.
64. Walker MP & Hong Z (2002) HCV RNA-dependent RNA polymerase as a target for antiviral development. Current Opinion in Pharmacoogy 2:1-7.
65. Walton E, Jenkins SR, Nutt RF & Holly FW (1969) Branched-chain sugar nucleosides. V. Synthesis and antiviral properties of several branched-chain sugar nucleosides. Journal of Medicinal Chemistry 12:306-309.
66. Wolf J, Jarrige J-M, Florent J-C, Grierson DS & Monneret C (1992) New 2′-C-branched-chain sugar nucleoside analogs with potential antiviral or antitumor activity. Synthesis:773-778.
67. Wolfe MS & Harry-O'kuru E (1995) A concise synthesis of 2′-C-methylribonucleosides. Tetrahedron Letters 36:7611-7614.
68. World Health Organization. (2000) Hepatitis C. Fact sheet no164. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
69. World Health Organization. (2002) Dengue and dengue haemorrhagic fever. Fact sheet no117. Available from: http://www.who.int/mediacentre/ factsheets/fs117/en/index.html
70. World Health Organization. (2003) Influenza. Fact sheet no211. Available from: http://www.who.int/mediacentre/factsheets/ fs211/en/index.html
71. World Health Organization. (2007) Measles. Fact sheet no286. Available from: http://www.who.int/mediacentre/factsheets/ fs286/en/index.html
72. Zemlicka J (2000) Enantioselectivity of the antiviral effects of nucleoside analogues. Pharmacology & Therapeutics 85:251-266.
73. Zhou X-J, Adfhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McInery D, Fielman BA & Brown N (2005) Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV inhibitor: results of a phase I/II dose-escalation trial in patients with HCV-1 infection. Journal of Hepatology 42 Suppl 2:229.